Our Scientific Advisory Board
Six leaders in neuroscience, nucleic-acid therapeutics, drug development and rare disease advocacy — now guiding the search for treatments in Dynamin-1 (DNM1) epilepsy.
Robert H. Ring, PhD
Neurodevelopment Drug Development Leader
CEO, Kaerus Bioscience
A neuroscientist with 25+ years in CNS medicines R&D across Wyeth, Pfizer, Autism Speaks and Kaerus. He led Pfizer's Autism Research Unit, served as Chief Science Officer of Autism Speaks, and at Kaerus advanced KER-0193 for Fragile X syndrome into Phase 1 before the program was acquired by Servier in 2025.
Janaiah Kota, PhD
Nucleic Acid Therapeutics & Gene Therapy Leader
Former Executive Director, Molecular Therapeutics, Ultragenyx
19+ years of R&D experience across ASO, siRNA, miRNA, mRNA and AAV gene therapy. At Ultragenyx he led nucleic-acid discovery and platform strategy for rare genetic diseases; earlier he contributed to IND-enabling AAV programs and studies supporting EXONDYS 51. He remains an active contributor to rare disease advocacy groups and foundations.
Stuart Cain, PhD
VP, Business Development
Bowen's FX Therapeutics
A decade of studying the impact of genetic ion channel mutations in epilepsy — including drug discovery on seizure-suppressing channel blockers.
He then joined adMare BioInnovations to build rare neurological therapeutics companies, including Bowen's FX Therapeutics and its engineered FMRP replacement program.
Katherine Bonnycastle, PhD, FCCMG
Clinical Laboratory Geneticist
CHU Sainte-Justine
A CCMG-certified clinical laboratory geneticist and neuroscientist who trained for nearly a decade at the University of Edinburgh, including in Prof. Michael Cousin's lab studying presynaptic biology and synaptic vesicle recycling. Her 2023 DNM1 R237W study identified BMS-204352 as a potential repurposing candidate that accelerated synaptic vesicle endocytosis and reversed cellular, circuit and seizure phenotypes in mice.
Preveen Ramamoorthy, PhD
Biopharma R&D Executive · Rare Disease Advocate
A global biopharma R&D executive with 24+ years spanning monoclonal antibodies, cell therapies, vaccines, blood products and precision medicine — 50+ development programs and a $1B+ portfolio, with 15 FDA- or EU-licensed products including Synagis and FluMist. He has built CAP- and CLIA-accredited genomics labs in the US and India, leads in the Organization for Rare Diseases India, and is a passionate advocate for rare disease families.
Laura Ohl, PhD
Postdoctoral Fellow
COMBINEDBrain
Dr. Ohl is a cellular and molecular neuroscientist and science communicator. She is dedicated to advancing novel therapeutics and clinical trial preparedness for rare neurological diseases. Throughout her research career, she has focused on uncovering the underlying mechanisms of complex neurological disorders to drive the development of life-changing treatments.
Dr. Ohl bridges the gap between complex science and patient-centric strategy. She collaborates closely with patient advocacy organizations to build robust frameworks for disease-focused clinical trial readiness and to design impactful scientific communication strategies. By translating intricate medical data into accessible, actionable insights, she empowers patient communities and ensures their voices shape the drug development pipeline.
Accelerate the path from Dynamin-1 science to real therapies for families.
Together this board helps guide strategy, advance translation, and build connections that move promising science toward treatments.
01 · Science
Understand biology
02 · Translation
Advance programs
03 · Development
Build clinical path
04 · Families
Keep patients centered
Join our scientific network.
🔬 Join Our Scientific Board
Are you a researcher or clinician with expertise in rare epilepsies, gene therapy, or neurogenetics? We invite you to join our scientific advisory board and help guide our research strategy.
Email Us →